Trial Profile
The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions; Therapeutic Use
- Acronyms END-COVID
- Sponsors Ridgeback Biotherapeutics
- 17 Mar 2022 Status changed from recruiting to completed.
- 06 Jan 2022 Planned End Date changed from 8 Jan 2022 to 27 Mar 2022.
- 06 Jan 2022 Planned primary completion date changed from 16 Dec 2021 to 4 Mar 2022.